Skip Main Links
Prescribing Information
Important Safety Information
For Healthcare
Providers
Sign Me Up

What is XYWAV

XYWAV is the
first and only
low‑sodium* oxybate treatment for cataplexy and/or excessive daytime sleepiness (EDS) in narcolepsy

*XYWAV contains 131 mg of sodium at the maximum recommended nightly dose.


Jump to:
  • Study Results
A man discussing his narcolepsy symptoms with a doctor

XYWAV, taken at night, is thought to work during sleep to help improve 2 common symptoms of narcolepsy during the day

XYWAV is the first and only low‑sodium oxybate approved by the FDA for treating cataplexy and/or EDS in people ages 7 years and older with narcolepsy.

XYWAV can be taken in addition to daytime medications like stimulants. Be sure to talk to your doctor about any medications you are taking or plan to take.

  • The exact way XYWAV works for the treatment of cataplexy and EDS in patients with narcolepsy is unknown.
Taking XYWAV

How was XYWAV studied?

The efficacy and safety of XYWAV was studied in 201 adults with narcolepsy with cataplexy who had at least 14 cataplexy attacks in a typical 2‑week period before they took any treatment.‡§

All people in the clinical trial started treatment with XYWAV. The majority of participants (59%) continued taking their stimulant or wake‑promoting agent along with XYWAV.

Graphic showing how well XYWAV® worked in a 2-week clinical trialGraphic showing how well XYWAV® worked in a 2-week clinical trial
  • Study included people aged 18-70.
  • §Not everyone completed each part of the trial. Of the 201 patients, 134 were included in the 2-week period that measured how well XYWAV worked.

Results

From the end of the 2 weeks where people in the clinical study kept taking XYWAV to the end of the 2 weeks of the study that measured how well XYWAV worked...

In people who stopped taking XYWAV

Cataplexy increased by an average of 11.5 attacks per week

Daytime sleepiness increased by an average of 3

In people who continued taking XYWAV

Cataplexy increased by an average of 0.1 attacks per week

Daytime sleepiness increased by an average of 0

Ask about XYWAV

New to oxybate treatment and wondering if it may be right for you?

Take the Quiz
Up Arrow Icon
Sign Me Up

This site is intended for US residents only.

© 2024 Jazz Pharmaceuticals, Inc. US-XYW-2200245 Rev1124